// App-Quantinova.ai

CT233 : Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients

Researchers

Presenter

  • Massimo Cristofanilli

Principal Investigators

  • Milana Dolezal

  • Jay Lalezari

  • Hallgeir Rui

  • Bruce Patterson

  • Cha-Mei Tang

  • Daniel Adams

  • Qiang Zhang

  • Kazem Kazempour

  • Nader Pourhassan

  • Natalie Rabb

  • Kush Dhody

Medical Centers

  • Northwestern University, Chicago, IL

  • Pacific Hematology Oncology Associates, San Francisco, CA

  • Quest Clinical Research, San Francisco, CA

  • The Medical College of Wisconsin, Milwaukee, WI

  • IncellDx, San Carlos, CA

  • Creatv MicroTech, Inc., Potomac, MD

  • Amarex Clinical Research, Germantown, MD

  • CytoDyn, Inc., Vancouver, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Triple-negative breast cancer

Biomarkers

  • C-C Motif Chemokine Receptor 5

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Carboplatin

  • PRO 140

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Single Arm

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved